2.Hepatitis B virus infection among children of hepatitis B surface antigen positive mothers in a Malaysian hospital
Wah-Kheong CHAN ; Kee-Ying YEOH ; Chia-Ying LIM ; Su-Meng LAI ; Jac-Lyn LEE ; Alex Hwong-Ruey LEOW ; Khean-Lee GOH
The Medical Journal of Malaysia 2018;73(3):137-140
transmission of hepatitis B virus (HBV) infection amongchildren of hepatitis B surface antigen (HBsAg) positivemothers in Malaysia. Methods: This is a cross-sectional study of all the childrenof HBsAg-positive mothers who delivered at the Universityof Malaya Medical Centre between 1993 and 2000. Results: A total of 60 HBsAg-positive mothers and their 154children participated in the study. HBsAg was detected infour children (2.6%) while IgG antibody to the hepatitis Bcore antigen (anti-HBc IgG) was detected in seventeenchildren (11.0%). The mother’s age at childbirth wassignificantly lower in the children with detectable HBsAg(22.5±6.1 years vs. 29.7±4.5 years, p=0.043) and anti-HBc IgG(26.6±6.1 years vs. 30.0±4.3 years, p=0.004). Children born inthe 1980s were significantly more likely to have detectableHBsAg (18.8% vs. 0.7%, p=0.004) and anti-HBc IgG (37.5%vs. 8.0%, p=0.000) compared with those born later. Allchildren with detectable HBsAg were born via spontaneousvaginal delivery, and hepatitis B immunoglobulin was eithernot given or the administration status was unknown. Themajority of mothers with chronic HBV infection (70.4%) werenot under any regular follow-up for their chronic HBVinfection and the main reason was the lack of awareness ofthe need to do so (47.4%). Conclusion: Transmission of HBV infection among childrenof HBsAg-positive mothers in Malaysia is low. However,attention needs to be given to the high rate of HBsAg-positive mothers who are not on any regular follow-up.
3.Epilepsy in Southeast Asia, how much have we closed the management gap in past two decades?
Kheng-Seang Lim ; Zhi-Jien Chia ; Moe-Zaw Myint ; Kazi Jannat Ara ; Yong-Chuan Chee ; Woon-Theng Heng ; Thanmidraaj-Kaur Balraj Singh ; Janice-Ying-Qian Ong ; Slocahnah SreeKumar ; Minh-An Thuy Lee ; Si-Lei Fong ; Chong-Tin Tan
Neurology Asia 2020;25(4):425-438
The last review on epilepsy in Southeast Asian (SEA) countries was reported in 1997. This review
aimed to update the understanding of epilepsy management in this region over the past 23 years. There
has been significant increase in the epidemiological studies which reported a prevalence of 4.3-7.7 per
1,000 populations in this region. Reversible aetiologies of epilepsy such as head injury, birth trauma,
cerebrovascular disease, and intracranial infections (neurocysticercosis or meningoencephalitis) are
still prevalent, with a surge in autoimmune encephalitis. There was a surge in genetic studies which
suggest ethnic variation. Treatment gap is still high especially in the rural and less developed areas,
and the availability and affordability of newer anti-epileptic drugs (AEDs) is still a major challenge
in SEA. Alternative medicine is a common practice but varies among different ethnic groups. AEDs
hypersensitivity especially on the association between HLA-B*1502 and carbamazepine-related severe
cutaneous reaction had been extensively studied and proven in nearly all SEA countries. However,
HLA-B*1502 screening is not widely available in SEA and the cost-effectiveness of the screening is
questionable. Stigma and its psychosocial consequences are still a major concern despite enormous
efforts to study the public attitudes towards epilepsy and change of epilepsy naming in a few countries.
The number and complexity of epilepsy surgery are progressing, but it is still under-utilized in many
SEA countries, related to cost, cultural perception and lack of facilities. More resources should also
be channelled in training adequate number of epileptologists who can spearhead epilepsy care around
the region, as well as public education and research in epilepsy. In conclusion, there is an increase in
epilepsy research in this region, gradual increase in trained neurologists and facilities, and efforts to
reduce the knowledge and treatment gap, but the epilepsy management gap is still a battle to fight.